Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.39
(-3.52%)
USD 0.39
(-3.52%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.07 Million USD | -29.69% |
| 2022 | 2.94 Million USD | 49.37% |
| 2021 | 1.97 Million USD | -22.4% |
| 2020 | 2.54 Million USD | -35.61% |
| 2019 | 3.94 Million USD | 101.48% |
| 2018 | 1.95 Million USD | 67.49% |
| 2017 | 1.16 Million USD | -58.95% |
| 2016 | 2.84 Million USD | -42.7% |
| 2015 | 4.97 Million USD | 1114.35% |
| 2014 | 409.27 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 2.16 Million USD | 25.28% |
| 2001 | 1.73 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.15 Million USD | 0.0% |
| 2024 Q2 | 1.83 Million USD | 0.0% |
| 2023 Q2 | 2.41 Million USD | -9.64% |
| 2023 Q3 | 2.14 Million USD | -11.29% |
| 2023 FY | 2.07 Million USD | -29.69% |
| 2023 Q4 | 2.07 Million USD | -3.45% |
| 2023 Q1 | 2.67 Million USD | -9.14% |
| 2022 Q3 | 2.23 Million USD | 51.01% |
| 2022 FY | 2.94 Million USD | 49.37% |
| 2022 Q2 | 1.47 Million USD | -18.21% |
| 2022 Q1 | 1.8 Million USD | -8.32% |
| 2022 Q4 | 2.94 Million USD | 31.9% |
| 2021 FY | 1.97 Million USD | -22.4% |
| 2021 Q1 | 2.24 Million USD | -11.69% |
| 2021 Q4 | 1.97 Million USD | 3.79% |
| 2021 Q3 | 1.89 Million USD | -9.31% |
| 2021 Q2 | 2.09 Million USD | -6.64% |
| 2020 FY | 2.54 Million USD | -35.61% |
| 2020 Q3 | 1.82 Million USD | -45.21% |
| 2020 Q2 | 3.33 Million USD | -7.1% |
| 2020 Q1 | 3.59 Million USD | -8.92% |
| 2020 Q4 | 2.54 Million USD | 38.87% |
| 2019 Q3 | 4.17 Million USD | 6.53% |
| 2019 Q4 | 3.94 Million USD | -5.49% |
| 2019 Q2 | 3.91 Million USD | -4.88% |
| 2019 FY | 3.94 Million USD | 101.48% |
| 2019 Q1 | 4.11 Million USD | 110.37% |
| 2018 Q2 | 1.03 Million USD | -5.41% |
| 2018 Q4 | 1.95 Million USD | 47.11% |
| 2018 Q3 | 1.33 Million USD | 29.1% |
| 2018 Q1 | 1.09 Million USD | -6.76% |
| 2018 FY | 1.95 Million USD | 67.49% |
| 2017 Q1 | 2.51 Million USD | -11.66% |
| 2017 Q2 | 1.39 Million USD | -44.52% |
| 2017 Q3 | 1.3 Million USD | -6.81% |
| 2017 Q4 | 1.16 Million USD | -10.15% |
| 2017 FY | 1.16 Million USD | -58.95% |
| 2016 Q2 | 2.38 Million USD | -60.65% |
| 2016 FY | 2.84 Million USD | -42.7% |
| 2016 Q1 | 6.05 Million USD | 21.81% |
| 2016 Q3 | 2.56 Million USD | 7.64% |
| 2016 Q4 | 2.84 Million USD | 11.08% |
| 2015 Q4 | 4.97 Million USD | 14.07% |
| 2015 FY | 4.97 Million USD | 1114.35% |
| 2015 Q1 | 578.27 Thousand USD | 41.29% |
| 2015 Q2 | 3.33 Million USD | 476.54% |
| 2015 Q3 | 4.35 Million USD | 30.68% |
| 2014 Q3 | 44.96 Thousand USD | -21.8% |
| 2014 FY | 409.27 Thousand USD | 0.0% |
| 2014 Q2 | 57.5 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 409.27 Thousand USD | 810.24% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q3 | 52.64 Thousand USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q2 | 2.24 Million USD | -2.55% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | 2.3 Million USD | 6.45% |
| 2003 Q3 | - USD | -100.0% |
| 2002 FY | 2.16 Million USD | 25.28% |
| 2002 Q2 | 1.92 Million USD | 5.67% |
| 2002 Q1 | 1.82 Million USD | 5.4% |
| 2002 Q3 | 2.04 Million USD | 5.93% |
| 2002 Q4 | 2.16 Million USD | 6.19% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | 1.73 Million USD | 0.0% |
| 2001 Q4 | 1.73 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -318.182% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 97.485% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | -31.679% |
| Azitra, Inc. | 563.69 Thousand USD | -267.222% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -15823.077% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | -0.485% |
| CEL-SCI Corporation | 11.6 Million USD | 82.159% |
| iBio, Inc. | 3.5 Million USD | 40.975% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 28.497% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -10.594% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -86.823% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 61.681% |
| BiomX Inc. | 5.4 Million USD | 61.681% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | 55.205% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -1163.875% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 83.589% |
| Theriva Biologics, Inc. | 162 Thousand USD | -1177.778% |